138 related articles for article (PubMed ID: 387323)
1. The effect of tamoxifen and stilboestrol on plasma hormone levels in postmenopausal women with advanced breast cancer.
McFadyen IJ; Raab G; Forrest AP; Langlands AO; Stewart HJ; Roberts MM; Hamilton T; Golder MP; Groom GV; Griffiths K
Clin Oncol; 1979 Sep; 5(3):251-6. PubMed ID: 387323
[No Abstract] [Full Text] [Related]
2. The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.
Stewart HJ; Forrest AP; Gunn JM; Hamilton T; Langlands AO; McFadyen IJ; Roberts MM
Eur J Cancer (1965); 1980; Suppl 1():83-8. PubMed ID: 7032945
[No Abstract] [Full Text] [Related]
3. Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer.
Blackburn AM; Wang DY; Bulbrook RD; Thomas BS; Kwa HG; Hoare SA; Rubens RD
Cancer Treat Rep; 1984 Dec; 68(12):1447-53. PubMed ID: 6239689
[TBL] [Abstract][Full Text] [Related]
4. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
5. Endocrine status in stage II vs. advanced premenopausal and postmenopausal breast cancer patients.
Bhatavdekar JM; Patel DD; Shah NG; Giri DD; Vora HH; Karelia NH; Trivedi SN; Ghosh N; Suthar TP
Neoplasma; 1992; 39(1):39-42. PubMed ID: 1388248
[TBL] [Abstract][Full Text] [Related]
6. Peptide and steroid hormone levels in pre- and postmenopausal breast carcinoma.
Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH
Neoplasma; 1987; 34(1):95-9. PubMed ID: 3104809
[TBL] [Abstract][Full Text] [Related]
7. [Buserelin therapy in postmenopausal patients with advanced breast carcinoma].
Vici P; Veltri E; Carpano S; Di Lauro L; Lopez M
Clin Ter; 1991 Feb; 136(3):195-9. PubMed ID: 1827382
[TBL] [Abstract][Full Text] [Related]
8. Serum hormones in human breast cancer subjects.
Krishnamoorthy G; Govindarajulu P; Ramalingam V
Neoplasma; 1989; 36(2):221-31. PubMed ID: 2497392
[TBL] [Abstract][Full Text] [Related]
9. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma.
Sawka CA; Pritchard KI; Paterson AH; Sutherland DJ; Thomson DB; Shelley WE; Myers RE; Mobbs BG; Malkin A; Meakin JW
Cancer Res; 1986 Jun; 46(6):3152-6. PubMed ID: 3084082
[TBL] [Abstract][Full Text] [Related]
10. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
Ravdin PM; Fritz NF; Tormey DC; Jordan VC
Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
[TBL] [Abstract][Full Text] [Related]
11. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Pannuti F; Martoni A; Farabegoli G; Piana E
Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease.
Malarkey WB; Schroeder LL; Stevens VC; James AG; Lanese RR
Cancer Res; 1977 Dec; 37(12):4655-9. PubMed ID: 922746
[TBL] [Abstract][Full Text] [Related]
13. [Steroid receptor levels in human breast carcinomas in relation to serum hormone levels in postmenopausal patients (author's transl)].
Reiner G; Bieglmayer C; Jakesz R; Kees A; Kolb R; Spona J
Wien Klin Wochenschr; 1981 May; 93(11):339-42. PubMed ID: 6791390
[TBL] [Abstract][Full Text] [Related]
14. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
Wilking N; Carlström K; Sköldefors H; Theve NO; Wallgren A
Acta Chir Scand; 1982; 148(4):345-9. PubMed ID: 6215811
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.
Mouridsen HT; Salimtschik M; Dombernowsky P; Gelshoj K; Palshof T; Rorth M; Daehnfeldt JL; Rose C
Eur J Cancer (1965); 1980; Suppl 1():107-10. PubMed ID: 7032918
[No Abstract] [Full Text] [Related]
16. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
17. Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients.
Rose DP; Chlebowski RT; Connolly JM; Jones LA; Wynder EL
Cancer Res; 1992 Oct; 52(19):5386-90. PubMed ID: 1394142
[TBL] [Abstract][Full Text] [Related]
18. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB
Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310
[TBL] [Abstract][Full Text] [Related]
19. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen.
Lahti E; Vuopala S; Kauppila A; Blanco G; Ruokonen A; Laatikainen T
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):410-4. PubMed ID: 7835781
[TBL] [Abstract][Full Text] [Related]
20. Sex hormones in postmenopausal women with breast cancer on tamoxifen.
Kostoglou-Athanassiou I; Ntalles K; Gogas J; Markopoulos C; Alevizou-Terzaki V; Athanassiou P; Georgiou E; Proukakis C
Horm Res; 1997; 47(3):116-20. PubMed ID: 9050950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
